沃拉西尼

Description

Vorasidenib · CAS 1644545-52-7 · C14H13ClF6N6. UNII 789Q85GA8P.

Identification

CAS Registry Number	1644545-52-7
PubChem CID	117817422
Molecular formula	C14H13ClF6N6
IUPAC name	6-(6-chloro-2-pyridinyl)-2-N,4-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine
UNII (FDA)	789Q85GA8P

Computed Descriptors

Molecular Weight	414.74
XLogP3	5.3
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	12
Rotatable Bond Count	5
Exact Mass	414.0794411
Monoisotopic Mass	414.0794411
Topological Polar Surface Area	75.6
Heavy Atom Count	27
Formal Charge	0

Documented Uses

• Vorasidenib is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation following surgery including biopsy, sub-total resection, or gross total resection.
• Vorasidenib is an orally available, small molecule inhibitor of mutatedisocitrate dehydrogenase-1 and -2 (IDH1 and IDH2) that is used in thetreatment of brain tumors (astrocytoma and oligodendroglioma) with IDHmutations. Vorasidenib is associated with a high rate of serumaminotransferase elevations during therapy and has been linked to rareinstances of clinically apparent liver injury, including an autoimmune-likehepatitis and acute liver failure.
• Take with or without food. A high-fat and high-calorie increases vorasidenib and Cmax, but not to a clinically significant extent.
• Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
• Established Pharmacologic Class [EPC] - Isocitrate Dehydrogenase 1 Inhibitor
• Established Pharmacologic Class [EPC] - Isocitrate Dehydrogenase 2 Inhibitor

Synonyms

Vorasidenib; 1644545-52-7; AG-881; Voranigo; AG881; 6-(6-chloropyridin-2-yl)-2-N,4-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; 789Q85GA8P; 1,3,5-Triazine-2,4-diamine, 6-(6-chloro-2-pyridinyl)-N2,N4-bis[(1R)-2,2,2-trifluoro-1-methylethyl]-; 1,3,5-Triazine-2,4-diamine, 6-(6-chloro-2-pyridinyl)-N2,N4-bis((1R)-2,2,2-trifluoro-1-methylethyl)-; vorasidenibum; 6-(6-chloropyridin-2-yl)-2-N,4-N-bis((2R)-1,1,1-trifluoropropan-2-yl)-1,3,5-triazine-2,4-diamine; AG 881; RefChem:902054; Vorasidenib [INN]; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoropropan-2-yl)-1,3,5-triazine-2,4-diamine; Vorasidenib [USAN]

Frequently Asked Questions

What are the CAS number and molecular formula of Vorasidenib?

CAS 1644545-52-7; molecular formula C14H13ClF6N6; molecular weight — g/mol.

What other names is Vorasidenib known by?

Vorasidenib, 1644545-52-7, AG-881, Voranigo, AG881, 6-(6-chloropyridin-2-yl)-2-N,4-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.